Identification of 3 novel VHL germ-line mutations in Danish VHL patients

BMC Medical Genetics

Thomas v O Hansen¹  Finn C Nielsen¹  Lone Sunde²  Lennart Friis-Hansen¹  Mette Dandanell¹ 

[1] Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;Department of Clinical Genetics, Aalborg Hospital, Aalborg, Denmark

关键词: Danish population;    Germ-line mutations;    VHL;    von Hippel-Lindau disease;   

Others  :  1177837
DOI  :  10.1186/1471-2350-13-54

 received in 2012-01-25, accepted in 2012-06-29,  发布年份 2012

【 摘 要 】

Background

von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome in which the patients develop retinal and central nervous system hemangioblastomas, pheochromocytomas and clear-cell renal tumors. The autosomal dominant disease is caused by mutations in the VHL gene.

Methods

VHL mutational analysis was carried out by sequencing of the coding sequence and by multiplex ligation-dependent probe amplification analysis. The functional consequence of the variants was investigated using in silico prediction tools.

Results

A total of 289 probands suspected of having VHL syndrome have been screened for mutations in the VHL gene. Twenty-six different VHL mutations were identified in 36 families including one in-frame duplication, two frame-shift mutations, four nonsense mutations, twelve missense mutations, three intronic mutations and four large genomic rearrangements. Three of these mutations (c.319 C > T, c.342_343dupGGT and c.520_521dupAA) were novel.

Conclusions

In this study we report the VHL germ-line mutations found in Danish families. We found three novel VHL mutations where two were classified as pathogenic and the latter was classified as a variant of unknown significance. Together, our findings contribute to the interpretation of the potential pathogenicity of VHL germ-line mutations.

【 授权许可】

   
2012 Dandanell et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Maher ER: Von Hippel-Lindau disease. Curr Mol Med 2004, 4:833-842.
• [2]Kaelin WG: Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002, 2:673-682.
• [3]Schoenfeld A, Davidowitz EJ, Burk RD: A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci U S A 1998, 95:8817-8822.
• [4]Iliopoulos O, Ohh M, Kaelin WG: pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A 1998, 95:11661-11666.
• [5]Blankenship C, Naglich JG, Whaley JM, Seizinger B, Kley N: Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 1999, 18:1529-1535.
• [6]Stebbins CE, Kaelin WG, Pavletich NP: Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999, 284:455-461.
• [7]Poulsen ML, Budtz-Jorgensen E, Bisgaard ML: Surveillance in von Hippel-Lindau disease (vHL). Clin Genet 2010, 77:49-59.
• [8]Poulsen ML, Gimsing S, Kosteljanetz M, Moller HU, Brandt CA, Thomsen C, Bisgaard ML: von Hippel-Lindau disease: Surveillance strategy for endolymphatic sac tumors. Genet Med 2011, 13:1032-1041.
• [9]von Hippel-Lindau reference program. http://www.ugeskriftet.dk/portal/page/portal/LAEGERDK/UGESKRIFT_FOR_LAEGER/KLINISKE_VAERKTOEJER/KLARINGSRAPPORTER/Von_Hippel-Lindaus_Sygdom.pdf webcite
• [10]Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de SD, Zharkikh A, Thomas A: Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006, 43:295-305.
• [11]Reese MG, Eeckman FH, Kulp D, Haussler D: Improved splice site detection in Genie. J Comput Biol 1997, 4:311-323.
• [12]Hebsgaard SM, Korning PG, Tolstrup N, Engelbrecht J, Rouze P, Brunak S: Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information. Nucleic Acids Res 1996, 24:3439-3452.
• [13]Yeo G, Burge CB: Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 2004, 11:377-394.
• [14]Hes FJ, van der Luijt RB, Janssen AL, Zewald RA, de Jong GJ, Lenders JW, Links TP, Luyten GP, Sijmons RH, Eussen HJ, Halley DJ, Lips CJ, Pearson PL, van den Ouweland AM, Majoor-Krakauer DF: Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification. Clin Genet 2007, 72:122-129.
• [15]Zhang J, Huang Y, Pan J, Liu D, Zhou L, Xue W, Chen Q, Dong B, Xuan H: Germline mutations in the von Hippel-Lindau disease (VHL) gene in mainland Chinese families. J Cancer Res Clin Oncol 2008, 134:1211-1218.
• [16]Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, Brauch H, Glavac D, Neumann HP, Tisherman S, Mulvihill JJ, Gross DJ, Shuin T, Whaley J, Seizinger B, Kley N, Olschwang S, Boisson C, Richard S, Lips CH, Lerman M: Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996, 8:348-357.
• [17]Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER: Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 2007, 28:143-149.
• [18]Siu WK, Ma RC, Lam CW, Mak CM, Yuen YP, Lo FM, Chan KW, Lam SF, Ling SC, Tong SF, So WY, Chow CC, Tang MH, Tam WH, Chan AY: Molecular basis of von Hippel-Lindau syndrome in Chinese patients. Chin Med J (Engl) 2011, 124:237-241.
• [19]Patocs A, Gergics P, Balogh K, Toth M, Fazakas F, Liko I, Racz K: Ser80Ile mutation and a concurrent Pro25Leu variant of the VHL gene in an extended Hungarian von Hippel-Lindau family. BMC Med Genet 2008, 9:29.
• [20]Brauch H, Kishida T, Glavac D, Chen F, Pausch F, Hofler H, Latif F, Lerman MI, Zbar B, Neumann HP: Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet 1995, 95:551-556.
• [21]Peyre M, Gaillard S, van Effenterre R, Giraud S, Richard S: Conservative management of endolymphatic sac tumors in von Hippel–Lindau disease: case report. Acta Neurochir 2011, 153:42-47.
• [22]Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE: Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res 2009, 15:7582-7592.
• [23]Erlic Z, Hoffmann MM, Sullivan M, Franke G, Peczkowska M, Harsch I, Schott M, Gabbert HE, Valimaki M, Preuss SF, Hasse-Lazar K, Waligorski D, Robledo M, Januszewicz A, Eng C, Neumann HP: Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. J Clin Endocrinol Metab 2010, 95:308-313.
• [24]Zhou MI, Wang H, Foy RL, Ross JJ, Cohen HT: Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent. Cancer Res 2004, 64:1278-1286.
• [25]Brauch H, Hoeppner W, Jahnig H, Wohl T, Engelhardt D, Spelsberg F, Ritter MM: Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene. J Clin Endocrinol Metab 1997, 82:4101-4104.
• [26]Pettman RK, Crowley A, Riddell C, Ludman MD: VHL P25L is not a pathogenic von Hippel-Lindau mutation: a family study. Mol Diagn Ther 2006, 10:239-242.
• [27]Miller F, Kentsis A, Osman R, Pan ZQ: Inactivation of VHL by Tumorigenic Mutations That Disrupt Dynamic Coupling of the pVHL-Hypoxia-inducible Transcription Factor-1alfa Complex. J Biol Chem 2005, 280:7985-7996.
• [28]Richards FM: Molecular pathology of von Hippel-Lindau disease and the VHL tumour suppressor gene. Expert Rev Mol Med 2001, 3:1-27.
• [29]Boedeker CC, Erlic Z, Richard S, Kontny U, Gimenez-Roqueplo AP, Cascon A, Robledo M, de Campos JM, van Nederveen FH, de Krijger RR, Burnichon N, Gaal J, Walter MA, Reschke K, Wiech T, Weber J, Rückauer K, Plouin PF, Darrouzet V, Giraud S, Eng C, Neumann HPH: Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2. J Clin Endocrinol Metab 2009, 94:1938-1944.
• [30]Botuyan MV, Mer G, Yi GS, Koth CM, Case DA, Edwards AM, Chazin WJ, Arrowsmith CH: Solution structure and dynamics of yeast elongin C in complex with a von Hippel-Lindau peptide. J Mol Biol 2001, 312:177-186.
• [31]Wiesener MS, Seyfarth M, Warnecke C, Jurgensen JS, Rosenberger C, Morgan NV, Maher ER, Frei U, Eckardt KU: Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002, 99:3562-3565.
• [32]Chong A, Zhang G, Bajic VB: Information for the Coordinates of Exons (ICE): a human splice sites database. Genomics 2004, 84:762-766.
• [33]Barry RE, Krek W: The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med 2004, 10:466-472.
• [34]Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, van den Ouweland AM, Majoor-Krakauer DF, Lolkema MP, van Brussel A, Voest EE, Giles RH: Genetic analysis of von Hippel-Lindau disease. Hum Mutat 2010, 31:521-537.